Last updated on August 2019

To Evaluate Safety Tolerability and Clinical Activity of the Antibody-drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A) or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)


Find a site near you

Start Over

GSK Investigational Site

Melbourne, Australia
2.08miles
  Connect »

GSK Investigational Site

Fitzroy, Australia
3.01miles
  Connect »